Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Momenta Pharmaceuticals Inc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Momenta Pharmaceuticals Inc (MNTA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2020
Competitors
237
Named by the company
Peer Group Market Share
100.00 %
vs 100.00 % a year ago
Revenue Growth Y/Y
27.56 %
Q2 2020
Net Margin
-862.81 %
Q2 2020

Key Findings: Momenta Pharmaceuticals Inc vs Its Competitors

  • TTM: Trailing 12-month revenue of 30M vs -M combined for its competitors (100.0% combined share).
  • Trending: Latest-quarter revenue run-rate is decelerating (-12.1% annualized vs trailing 12 months).
  • Peer revenue share: Momenta Pharmaceuticals Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

MNTA Sales vs. its Competitors, Q2 2020

Momenta Pharmaceuticals Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MNTA/competitors
https://api.csimarket.com/api/v1/companies/MNTA/relationships
https://api.csimarket.com/api/v1/companies/MNTA/similar
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API

For context: the Biotechnology & Pharmaceuticals industry grew revenue 21.4% year over year, combined, vs 27.6% for Momenta Pharmaceuticals Inc. Momenta Pharmaceuticals Inc's share of combined industry revenue moved from 0.01% to 0.01%, a gain of 0.00 percentage points.

Momenta Pharmaceuticals Inc's Competitor Quality Breadth

Group definitions: see Methodology: Performance Group Definitions.

Entity Profitable Expanding Above Industry Growth Distressed
Momenta Pharmaceuticals inc - No No No
High-Confidence Competitors (133) 44% 63% 43% 52%

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q2 2020

100%market share
  • Momenta Pharmaceuticals Inc100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of Momenta Pharmaceuticals Inc and its 237 competitors.

See Momenta Pharmaceuticals Inc's full market share breakdown »

MNTA Stock Performance relative to its Competitors

MNTA Competitors (weighted) Percent change over the selected range

Momenta Pharmaceuticals Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.
35.1%beat U.S.A. 500
High-Confidence
(39 of 111)
Entity TTM Share Price Return
(group: median)
vs U.S.A. 500
Momenta Pharmaceuticals inc - -
Competitors combined (0) 40.4% 63.2%
High-Confidence Competitors (111) 40.4% 63.2%
Similar-Size Competitors (0) 40.4% 63.2%
Similar Growth & Profitability (0) 40.4% 63.2%
Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Momenta Pharmaceuticals Inc's competitor groups requires a Commercial License.

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

MNTA Stock Performance relative to High-Confidence Competitors

MNTA High-Confidence Competitors (equal-weighted, 138) Percent change over the selected range

Momenta Pharmaceuticals Inc's Competitors Named by the Company

Competitive relationships identified from Momenta Pharmaceuticals Inc reports and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
Medtronic plc Company report 85% 2022 to 2026 3
Boston Scientific Corporation Company report 85% 2022 to 2026 3
Angiodynamics Inc Company report 85% 2022 to 2026 3
Intuitive Surgical Inc Company report 85% 2022 to 2026 3
Abbvie Inc Company report 85% 2022 to 2026 3
Encision Inc Company report 85% 2022 to 2026 3
Abbott Laboratories Company report 85% 2022 to 2026 3
United Health Products Inc Company report 85% 2022 to 2026 3
Co diagnostics Inc Company report 85% 2022 to 2026 3
Catheter Precision Inc Company report 85% 2022 to 2026 3
Integra Lifesciences Holdings Corp Company report 85% 2022 to 2026 3
Globus Medical Inc Company report 85% 2022 to 2026 3
Bioventus Inc Company report 85% 2022 to 2026 3
Koninklijke Philips Nv Company report 85% 2022 to 2026 3
Acutus Medical Inc Company report 85% 2022 to 2026 3
Novavax inc Company report 85% 2022 to 2026 3
Cardiovascular Systems, Inc. Company report 85% 2022 to 2026 3
Inspiremd Inc Company report 85% 2022 to 2026 3
Briacell Therapeutics Corp Company report 85% 2022 to 2026 3
Voyager Therapeutics Inc Company report 85% 2022 to 2026 3
Enovis Corp Company report 85% 2022 to 2026 3
Biodexa Pharmaceuticals Plc Company report 85% 2022 to 2026 3
Black Diamond Therapeutics Inc Company report 85% 2022 to 2026 3
Acumen Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Stryker Corp Company report 85% 2022 to 2026 3
Bristol myers Squibb Company Company report 85% 2022 to 2026 3
Vanda Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Paragon 28 inc Company report 85% 2022 to 2026 3
Monogram technologies inc Company report 85% 2022 to 2026 3
Mersana Therapeutics inc Company report 85% 2022 to 2026 3
Addex Therapeutics Ltd Company report 85% 2022 to 2026 3
Sutro Biopharma Inc Company report 85% 2022 to 2026 3
Apexigen Inc Company report 85% 2022 to 2026 3
Sellas Life Sciences Group Inc Company report 85% 2022 to 2026 3
Morphic Holding inc Company report 85% 2022 to 2026 3
Agentix Corp Company report 85% 2022 to 2026 3
Alpha Pro Tech Ltd Company report 85% 2022 to 2026 3
Pulse Biosciences Inc Company report 85% 2022 to 2026 3
Janux Therapeutics Inc Company report 85% 2022 to 2026 3
Bone Biologics Corporation Company report 85% 2022 to 2026 3
Abivax Sa Company report 85% 2022 to 2026 3
The Cooper Companies Inc Company report 85% 2022 to 2026 3
Spyglass Pharma Inc Company report 85% 2022 to 2026 3
Lenz Therapeutics Inc Company report 85% 2022 to 2026 3
Starco Brands Inc Company report 85% 2022 to 2026 3
Mangoceuticals Inc Company report 85% 2022 to 2026 3
Candel Therapeutics Inc Company report 85% 2022 to 2026 3
Immix Biopharma Inc Company report 85% 2022 to 2026 3
Compass Therapeutics Inc Company report 85% 2022 to 2026 3
Vor Biopharma Inc Company report 85% 2022 to 2026 3
Xtant Medical Holdings Inc Company report 85% 2022 to 2026 3
Arrivent Biopharma inc Company report 85% 2022 to 2026 3
Sana Biotechnology Inc Company report 85% 2022 to 2026 3
Kymera Therapeutics Inc Company report 85% 2022 to 2026 3
Gossamer Bio Inc Company report 85% 2022 to 2026 3
Shattuck Labs Inc Company report 85% 2022 to 2026 3
Nanobiotix S a Company report 85% 2022 to 2026 3
Arcellx Inc Company report 85% 2022 to 2026 3
Corbus Pharmaceuticals Holdings Inc Company report 85% 2022 to 2026 3
Actinium Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Pyxis Oncology Inc Company report 85% 2022 to 2026 3
Sintx Technologies Inc Company report 85% 2022 to 2026 3
Tempest Therapeutics Inc Company report 85% 2022 to 2026 3
Oragenics Inc Company report 85% 2022 to 2026 3
Curanex Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Ss Innovations International Inc Company report 85% 2022 to 2026 3
Scynexis Inc Company report 85% 2022 to 2026 3
Gh Research Plc Company report 85% 2022 to 2026 3
Cabaletta Bio Inc Company report 85% 2022 to 2026 3
Compass Pathways Plc Company report 85% 2022 to 2026 3
Nexgel Inc Company report 85% 2022 to 2026 3
Cytosorbents Corporation Company report 85% 2022 to 2026 3
Evolus Inc Company report 85% 2022 to 2026 3
Medinotec Inc Company report 85% 2022 to 2026 3
BSGM Company report 85% 2022 to 2026 3
NAYA Company report 85% 2022 to 2026 3
Nuvation Bio Inc Company report 85% 2022 to 2026 3
Alkermes Company report 85% 2022 to 2026 3
Cadrenal Therapeutics Inc Company report 85% 2022 to 2026 3
Bright Minds Biosciences Inc Company report 85% 2022 to 2026 3
Otsuka Pharmaceutical Company report 85% 2022 to 2026 3
Essa Pharma inc Company report 85% 2022 to 2026 3
Bicara Therapeutics Inc Company report 85% 2022 to 2026 3
Macrogenics Inc Company report 85% 2022 to 2026 3
Monopar Therapeutics Inc Company report 85% 2022 to 2026 3
Invo Fertility Inc Company report 85% 2022 to 2026 3
Greenwich Lifesciences Inc Company report 85% 2022 to 2026 3
Streamex Corp Company report 85% 2022 to 2026 3
Akero Therapeutics Inc Company report 85% 2022 to 2026 3
Igm Biosciences Inc Company report 85% 2022 to 2026 3
INVO Company report 85% 2022 to 2026 3
Definium Therapeutics Inc Company report 85% 2022 to 2026 3
Xoma Royalty Corporation Company report 85% 2022 to 2026 3
MNMD Company report 85% 2022 to 2026 3
Protagonist Therapeutics inc Company report 85% 2022 to 2026 3
Spyre Therapeutics Inc Company report 85% 2022 to 2026 3
Chemomab Therapeutics Ltd Company report 85% 2022 to 2026 3
Philips N.V. Company report 85% 2022 to 2026 3
Altamira Therapeutics Ltd Company report 85% 2022 to 2026 3
ENTO Company report 85% 2022 to 2026 3
Mira Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Gridai Technologies Corp Company report 85% 2022 to 2026 3
Neximmune Inc Company report 85% 2022 to 2026 3
Vincerx Pharma Inc Company report 85% 2022 to 2026 3
Church and Dwight Co Inc Company report 85% 2022 to 2026 3
Prestige Consumer Healthcare Inc Company report 85% 2022 to 2026 3
The Hain Celestial Group Inc Company report 85% 2022 to 2026 3
Absci Corp Company report 85% 2022 to 2026 3
Ngm Biopharmaceuticals Inc Company report 85% 2022 to 2026 3
Cue Biopharma Inc Company report 85% 2022 to 2026 3
Glucotrack Inc Company report 85% 2022 to 2026 3
Surrozen Inc Company report 85% 2022 to 2026 3
Mirati Therapeutics Inc Company report 85% 2022 to 2026 3
The Honest Company Inc Company report 85% 2022 to 2026 3
Arbutus Biopharma Corp Company report 85% 2022 to 2026 3
Immunome Inc Company report 85% 2022 to 2026 3
Assembly Biosciences Inc Company report 85% 2022 to 2026 3
Puretech Health Plc Company report 85% 2022 to 2026 3
Lineage Cell Therapeutics Inc Company report 85% 2022 to 2026 3
Staar Surgical Co Company report 85% 2022 to 2026 3
Inmune Bio Inc Company report 85% 2022 to 2026 3
Galapagos Nv Company report 85% 2022 to 2026 3
Ocugen Inc Company report 85% 2022 to 2026 3
Inflarx N V Company report 85% 2022 to 2026 3
Urogen Pharma Ltd Company report 85% 2022 to 2026 3
Allergan Company report 85% 2022 to 2026 3
Fusion Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Aytu Biopharma Inc Company report 85% 2022 to 2026 3
Sunovion Company report 85% 2022 to 2026 3
Autolus Therapeutics Plc Company report 85% 2022 to 2026 3
Reshape Lifesciences Inc Company report 85% 2022 to 2026 3
Alphatec Holdings Inc Company report 85% 2022 to 2026 3
Anavex Life Sciences Corp Company report 85% 2022 to 2026 3
Arena Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Perrigo Company Plc Company report 85% 2022 to 2026 3
Exagen Inc Company report 85% 2022 to 2026 3
Lyra Therapeutics Inc Company report 85% 2022 to 2026 3
Can fite Biopharma Ltd Company report 85% 2022 to 2026 3
Zevra Therapeutics Inc Company report 85% 2022 to 2026 3
4d Molecular Therapeutics Inc Company report 85% 2022 to 2026 3
Inovio Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Relmada Therapeutics Inc Company report 85% 2022 to 2026 3
Alzamend Neuro Inc Company report 85% 2022 to 2026 3
Anaptysbio Inc Company report 85% 2022 to 2026 3
Atricure Inc Company report 85% 2022 to 2026 3
Edwards Lifesciences Corporation Company report 85% 2022 to 2026 3
Livanova Plc Company report 85% 2022 to 2026 3
Cvrx inc Company report 85% 2022 to 2026 3
Ir med Inc Company report 85% 2022 to 2026 3
Adagio Medical Holdings inc Company report 85% 2022 to 2026 3
Meihua International Medical Technologies Co Ltd Company report 85% 2022 to 2026 3
Surmodics Inc Company report 85% 2022 to 2026 3
Transmedics Group Inc Company report 85% 2022 to 2026 3
Silk Road Medical Inc Company report 85% 2022 to 2026 3
Axogen inc Company report 85% 2022 to 2026 3
Penumbra Inc Company report 85% 2022 to 2026 3
Artivion Inc Company report 85% 2022 to 2026 3
Semler Scientific inc Company report 85% 2022 to 2026 3
Biohaven Ltd Company report 85% 2022 to 2026 3
Regeneron Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Takeda Pharmaceutical Company Limited Company report 85% 2022 to 2026 3
Si bone inc Company report 85% 2022 to 2026 3
Irhythm Holdings Inc Company report 85% 2022 to 2026 3
Danaher Corporation Company report 85% 2022 to 2026 3
Non Invasive Monitoring Systems Inc Company report 85% 2022 to 2026 3
Eli Lilly And Company Company report 85% 2022 to 2026 3
Smith and Nephew Plc Company report 85% 2022 to 2026 3
Bausch and Lomb Corp Company report 85% 2022 to 2026 3
Novartis Ag Company report 85% 2022 to 2026 3
Conmed Corporation Company report 85% 2022 to 2026 3
Pfizer Inc Company report 85% 2022 to 2026 3
Gilead Sciences Inc Company report 85% 2022 to 2026 3
Sage Therapeutics Inc Company report 85% 2022 to 2026 3
Baxter International Inc Company report 85% 2022 to 2026 3
Vertex Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Surgalign Holdings Inc Company report 85% 2022 to 2026 3
Pacira Biosciences inc Company report 85% 2022 to 2026 3
Horizon Therapeutics Public Limited Company Company report 85% 2022 to 2026 3
Establishment Labs Holdings Inc Company report 85% 2022 to 2026 3
Nuvasive Inc Company report 85% 2022 to 2026 3
Unilever Plc Company report 85% 2022 to 2026 3
Merck and Co Inc Company report 85% 2022 to 2026 3
Gsk Plc Company report 85% 2022 to 2026 3
Orchestra Biomed Holdings Inc Company report 85% 2022 to 2026 3
Merit Medical Systems Inc Company report 85% 2022 to 2026 3
Jazz Pharmaceuticals Plc Company report 85% 2022 to 2026 3
Atrion Corporation Company report 85% 2022 to 2026 3
Moderna Inc Company report 85% 2022 to 2026 3
Sanofi Company report 85% 2022 to 2026 3
Lemaitre Vascular Inc Company report 85% 2022 to 2026 3
Procter and Gamble Co Company report 85% 2022 to 2026 3
Inari Medical Inc Company report 85% 2022 to 2026 3
Organon and Co Company report 85% 2022 to 2026 3
Tiziana Life Sciences Ltd Company report 85% 2022 to 2026 3
Alexion Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Teleflex Incorporated Company report 85% 2022 to 2026 3
Bellicum Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Est e Lauder Companies Inc Company report 85% 2022 to 2026 3
Humanigen Inc Company report 85% 2022 to 2026 3
Vicarious Surgical Inc Company report 85% 2022 to 2026 3
Nektar Therapeutics Company report 85% 2022 to 2026 3
Axsome Therapeutics Inc Company report 85% 2022 to 2026 3
Prometheus Biosciences Inc Company report 85% 2022 to 2026 3
Viatris Inc Company report 85% 2022 to 2026 3
Affimed N v Company report 85% 2022 to 2026 3
Xencor Inc Company report 85% 2022 to 2026 3
Becton Dickinson And Company Company report 85% 2022 to 2026 3
3m Company Company report 85% 2022 to 2026 3
Aptinyx Inc Company report 85% 2022 to 2026 3
Zimvie Inc Company report 85% 2022 to 2026 3
Stereotaxis Inc Company report 85% 2022 to 2026 3
Insulet Corporation Company report 85% 2022 to 2026 3
Thermo Fisher Scientific Inc Company report 85% 2022 to 2026 3
Amgen Inc Company report 85% 2022 to 2026 3
Inspire Medical Systems inc Company report 85% 2022 to 2026 3
Bolt Biotherapeutics Inc Company report 85% 2022 to 2026 3
Colgate palmolive Company Company report 85% 2022 to 2026 3
Legend Biotech Corporation Company report 85% 2022 to 2026 3
Procept Biorobotics Corporation Company report 85% 2022 to 2026 3
Asensus Surgical Inc Company report 85% 2022 to 2026 3
Nkarta Inc Company report 85% 2022 to 2026 3
Cerevel Therapeutics Holdings Inc Company report 85% 2022 to 2026 3
Teva Pharmaceutical Industries Limited Company report 85% 2022 to 2026 3
Alcon inc Company report 85% 2022 to 2026 3
Zimmer Biomet Holdings Inc Company report 85% 2022 to 2026 3
Biogen Inc Company report 85% 2022 to 2026 3
Journey Medical Corp Company report 85% 2022 to 2026 3
Karuna Therapeutics Inc Company report 85% 2022 to 2026 3
Cervomed Inc Company report 85% 2022 to 2026 3
Arcus Biosciences Inc Company report 85% 2022 to 2026 3
United Therapeutics Corporation Company report 85% 2022 to 2026 3
Bausch Health Companies Inc Company report 85% 2022 to 2026 3
Astrazeneca Plc Company report 85% 2022 to 2026 3
Conformis inc Company report 85% 2022 to 2026 3
Fortress Biotech Inc Company report 85% 2022 to 2026 3
Lexicon Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Minerva Neurosciences Inc Company report 85% 2022 to 2026 3
Competitor Evidence Detail

Company report basis, confidence, active dates and source counts for Momenta Pharmaceuticals Inc's named competitors require a Commercial License.

Methodology: see Methodology: Peer & Competitor Identification, Sourcing.

Get the full CSIMarket dataset: Subscribe API Connect Your AI